Price
CHART BY
Frequently asked questions
What is Beyond's market capitalization?
The market capitalization of Beyond is $29.10M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Beyond?
Beyond's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.406. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Beyond's stock?
Currently, 5 analysts cover Beyond's stock, with a consensus target price of $2.50. Analyst ratings provide insights into the stock's expected performance.
What is Beyond's revenue over the trailing twelve months?
Over the trailing twelve months, Beyond reported a revenue of $2.34M.
What is the EBITDA for Beyond?
Beyond's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$52.84M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Beyond?
Beyond has a free cash flow of -$55.19M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Beyond have, and what sector and industry does it belong to?
Beyond employs approximately 107 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Beyond's shares?
The free float of Beyond is 61.84M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $29.10M
- EPS (TTM)
- -$1.406
- Free Float
- 61.84M
- Revenue (TTM)
- $2.34M
- EBITDA (TTM)
- -$52.84M
- Free Cashflow (TTM)
- -$55.19M
Pricing
- 1D span
- $0.402$0.411
- 52W span
- $0.296$2.35
Analyst Ratings
The price target is $2.50 and the stock is covered by 5 analysts.
Buy
4
Hold
1
Sell
0
Information
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.
- Employees
- 107
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- US08862L1035
- Primary Ticker
- XAIR